Be a part of MIST clinical trials that will save lives
Research highlight
MIST clinical trial to explore potential of psychedelics combined with therapy to help people reduce or stop drinking
UCalgary researchers are set to conduct Canada’s largest single-site clinical trial to find out if combining psychotherapy with psilocybin (the active component of “magic mushrooms") is a viable treatment for alcohol use disorder (AUD).
Evidence has recently shown that psilocybin-assisted psychotherapy may help some individuals in reducing their alcohol consumption, but how or why it works (or whom it will work for) is not understood.
Principal investigator Dr. Leah Mayo, PhD, Parker Chair in Psychedelics at the Cumming School of Medicine and MIST research team member, will lead this important clinical trial.
Goals of MIST clinical trials
Clinical trials advance MIST’s reach and impact
Clinical trials measure the safety and effectiveness of medical treatments and interventions. They are essential to advancing medical knowledge and ensuring countless people here and around the world can access safe and effective new treatments. MIST clinical trials are conducting important research to unlock new treatments for mental health conditions associated with emotional stress and head trauma such as major depression, post-concussion syndrome, and post-traumatic stress disorder.
You can find MIST trials that are currently accepting participants through the Participate in Research database (PiR). PiR is a searchable directory for community members to connect with researchers recruiting participants. Through PiR, you can find MIST clinical trials by entering research topic-related search terms (eg. head trauma or depression) or the name of the MIST research team investigator.